GFAP antibody

Catalog No. ABIN94316

The Mouse Monoclonal anti-GFAP antibody has been validated for WB, ICC, IHC (p) and IHC (fro). It is suitable to detect GFAP in samples from Human and Pig. There is 1 publication available.

Quick Overview for GFAP antibody (ABIN94316)

Target: GFAP (Glial Fibrillary Acidic Protein (GFAP))

Reactivity: Human, Pig

Host: Mouse

Clonality: Monoclonal

Conjugate: This GFAP antibody is un-conjugated

Application: Western Blotting (WB), Immunocytochemistry (ICC), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Clone: GF-02

Product Details anti-GFAP Antibody

Purpose: Anti-GFAP Purified

Specificity: The mouse monoclonal antibody GF-02 exclusively reacts with intact GFAP molecules. GFAP is the principal marker of astroglial cells in the central nervous system, it is specifically expressed in satellite cells in peripheral ganglia and in non myelinating Schwann cells in peripheral nerves. The GFAP protein runs on gels at ~55 kDa protein, usually associated with lower Mw bands which are thought to be proteolytic fragments and alternate transcripts from the single gene.

Cross-Reactivity (Details): Human, Porcine

Purification: Purified by sequential steps of physicochemical fractionation (differential precipitation and solid-phase chromatography methods).

Purity: > 95 % (by SDS-PAGE)

Immunogen: Pellet of porcine brain cold-stable proteins after depolymerization of microtubules.

Isotype: IgM

Application Details

Application Notes: Western blotting: Recommended dilution: 1-2 μg/mL.

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: Tris buffered saline (TBS), pH 8.0, 15 mM sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Do not freeze.

Storage: 4 °C

Storage Comment: Store at 2-8°C. Do not freeze.

References for anti-GFAP antibody (ABIN94316)

Porchet, Probst, Bouras, Dráberová, Dráber, Riederer: "Analysis of glial acidic fibrillary protein in the human entorhinal cortex during aging and in Alzheimer's disease." in: Proteomics, Vol. 3, Issue 8, pp. 1476-85, (2003) (PubMed).

Target Details for GFAP

Target: GFAP (Glial Fibrillary Acidic Protein (GFAP))

Alternative Name: GFAP

Background: Glial fibrillary acidic proteinprovided,GFAP (glial fibrillary acidic protein) was discovered by Bignami et al. (1972) as a major fibrous protein of multiple sclerosis plaques. It was subsequently found to be a member of the 10 nm or intermediate filament protein family, specifically the intermediate filament protein family class III, which also includes peripherin, desmin and vimentin. GFAP is heavily, and specifically, expressed in astrocytes and certain other astroglia in the central nervous system, in satellite cells in peripheral ganglia, and in non-myelinating Schwann cells in peripheral nerves. In addition, neural stem cells frequently strongly express GFAP. It is also found in the lens epithelium, Kupffer cells of the liver, in some cells in salivary tumors and has been reported in erythrocytes. Although its function is not fully understood, GFAP protein is probably involved in controlling the shape and movement of astrocytes. The protein probably also plays a significant role in the interactions of astrocytes with other cells, which are required for the formation and maintenance of the insulating layer (myelin) that covers nerve cells. Additionally, GFAP protein may assist in maintaining the protective barrier that allows only certain substances to pass between blood vessels and the brain (blood-brain barrier).In adults, GFAP levels increase as a result of the proliferation of astrocytes that occurs in a response to a variety of physical, chemical and etiological insults, including Alzheimer’,s disease, epilepsy and multiple sclerosis.Antibodies to GFAP are therefore very useful as markers of astrocytic cells and neural stem cells and for distinguishing of neoplasms of astrocytic origin from other neoplasms in the central nervous system. Finally, Alexander's disease was recently shown to be caused by point mutations in protein coding region of the GFAP gene (Brenner et al., 2001). All forms of Alexander disease are characterized by the presence of Rosenthal fibers, which are GFAP containing cytoplasmic inclusions found in astrocytes.,GFAP, ALXDRD

Gene ID: 2670

UniProt: P14136